High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease

M A Lumley; D W Milligan; C J Knechtli; S G Long; L J Billingham; D F McDonald

High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease

M A Lumley, D W Milligan, C J Knechtli, S G Long, L J Billingham, D F McDonald

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

Forty-two patients with relapsed or refractory Hodgkin's disease (HD) were treated with high-dose chemotherapy (BEAM regimen) followed by autologous bone marrow and/or peripheral blood progenitor cell (PBPC) rescue. There was one procedure-related death and the overall response rate at 6 months was 88% (95% confidence interval 78-98%). The 2 year overall and event-free survival was 81% (95% confidence interval 65-96%) and 74% (95% confidence interval 58-89%) respectively. Median follow-up was 33 months. The use of PBPC instead of marrow resulted in a significant shortening of the time to engraftment (P

Original language	English
Pages (from-to)	383-8
Number of pages	6
Journal	Bone Marrow Transplantation
Volume	17
Issue number	3
Publication status	Published - Mar 1996

Keywords

Adolescent
Adult
Antineoplastic Combined Chemotherapy Protocols
Bone Marrow Transplantation
Carmustine
Combined Modality Therapy
Cytarabine
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation
Hodgkin Disease
Humans
L-Lactate Dehydrogenase
Male
Melphalan
Middle Aged
Podophyllotoxin
Prognosis
Recurrence
Survival Rate
Transplantation, Autologous
Treatment Outcome

Cite this

@article{c027b9833e684d8ca9b8019f3808c208,

title = "High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease",

abstract = "Forty-two patients with relapsed or refractory Hodgkin's disease (HD) were treated with high-dose chemotherapy (BEAM regimen) followed by autologous bone marrow and/or peripheral blood progenitor cell (PBPC) rescue. There was one procedure-related death and the overall response rate at 6 months was 88% (95% confidence interval 78-98%). The 2 year overall and event-free survival was 81% (95% confidence interval 65-96%) and 74% (95% confidence interval 58-89%) respectively. Median follow-up was 33 months. The use of PBPC instead of marrow resulted in a significant shortening of the time to engraftment (P ",

keywords = "Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Bone Marrow Transplantation, Carmustine, Combined Modality Therapy, Cytarabine, Female, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Hodgkin Disease, Humans, L-Lactate Dehydrogenase, Male, Melphalan, Middle Aged, Podophyllotoxin, Prognosis, Recurrence, Survival Rate, Transplantation, Autologous, Treatment Outcome",

author = "Lumley, {M A} and Milligan, {D W} and Knechtli, {C J} and Long, {S G} and Billingham, {L J} and McDonald, {D F}",

year = "1996",

month = mar,

language = "English",

volume = "17",

pages = "383--8",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease

AU - Lumley, M A

AU - Milligan, D W

AU - Knechtli, C J

AU - Long, S G

AU - Billingham, L J

AU - McDonald, D F

PY - 1996/3

Y1 - 1996/3

N2 - Forty-two patients with relapsed or refractory Hodgkin's disease (HD) were treated with high-dose chemotherapy (BEAM regimen) followed by autologous bone marrow and/or peripheral blood progenitor cell (PBPC) rescue. There was one procedure-related death and the overall response rate at 6 months was 88% (95% confidence interval 78-98%). The 2 year overall and event-free survival was 81% (95% confidence interval 65-96%) and 74% (95% confidence interval 58-89%) respectively. Median follow-up was 33 months. The use of PBPC instead of marrow resulted in a significant shortening of the time to engraftment (P

AB - Forty-two patients with relapsed or refractory Hodgkin's disease (HD) were treated with high-dose chemotherapy (BEAM regimen) followed by autologous bone marrow and/or peripheral blood progenitor cell (PBPC) rescue. There was one procedure-related death and the overall response rate at 6 months was 88% (95% confidence interval 78-98%). The 2 year overall and event-free survival was 81% (95% confidence interval 65-96%) and 74% (95% confidence interval 58-89%) respectively. Median follow-up was 33 months. The use of PBPC instead of marrow resulted in a significant shortening of the time to engraftment (P

KW - Adolescent

KW - Adult

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Bone Marrow Transplantation

KW - Carmustine

KW - Combined Modality Therapy

KW - Cytarabine

KW - Female

KW - Follow-Up Studies

KW - Hematopoietic Stem Cell Transplantation

KW - Hodgkin Disease

KW - Humans

KW - L-Lactate Dehydrogenase

KW - Male

KW - Melphalan

KW - Middle Aged

KW - Podophyllotoxin

KW - Prognosis

KW - Recurrence

KW - Survival Rate

KW - Transplantation, Autologous

KW - Treatment Outcome

M3 - Article

C2 - 8704691

SN - 0268-3369

VL - 17

SP - 383

EP - 388

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 3

ER -

High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease

Abstract

Keywords

Fingerprint

Cite this